Duane Morris‘ work on the sale of startup company client Vicept Therapeutics is evidence that one good deed can lead to another, or, perhaps, one good deal to another.

Philadelphia-based corporate partner Yves Quintin led the firm’s work in 2009 and 2010 on the $350 million sale of client Ception Therapeutics to pharmaceutical company Cephalon . That deal also provided the potential for an additional $500 million in milestone payments.